• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Sep 1993; 92(3): 1296–1301.
PMCID: PMC288271

The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).


HLA class II alleles were determined using the PCR-RFLP method in Japanese systemic sclerosis (scleroderma) patients with (n = 28) or without (n = 34) anti-topoisomerase I antibodies (anti-topo I). Either the DQB1*0601 or *0301 allele was recognized in all anti-topo I positive patients, compared with 44% of anti-topo I negative patients (P < 0.00001, relative risk [RR] > 41) or 58% of Japanese healthy control subjects (P < 0.00001, RR > 24). Tyrosine at position 26 in the second hypervariable region in the beta 1 domain of the DQB1 gene is common to these two alleles and is not present in any other known DQB1 alleles. We also examined immunoreactivities of anti-topo I positive sera to four different autoantigenic B cell epitopes of topo I molecule that were expressed as recombinant fusion proteins. One major B cell epitope, located within the region corresponding to amino acid residues 74-248, was perfectly associated with the amino acid sequence FLEDR at positions 67-71 in the beta 1 domain of the DRB gene. Two other epitopes, corresponding to 316-441 or 658-700, were associated with the serologically defined HLA-DR52 antigen. Patients with both FLEDR and DR52 demonstrated higher anti-topo I antibody titers. These results suggest that the HLA-DR and DQ genes together control the autoimmune response to topo I in systemic sclerosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980 Jun;23(6):617–625. [PubMed]
  • Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980 Oct;69(4):520–526. [PubMed]
  • Steen VD, Ziegler GL, Rodnan GP, Medsger TA., Jr Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984 Feb;27(2):125–131. [PubMed]
  • Nishikai M, Okano Y, Yamashita H, Watanabe M. Characterisation of centromere (kinetochore) antigen reactive with sera of patients with a scleroderma variant (CREST syndrome). Ann Rheum Dis. 1984 Dec;43(6):819–824. [PMC free article] [PubMed]
  • Steen VD, Powell DL, Medsger TA., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. [PubMed]
  • Weiner ES, Earnshaw WC, Senécal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988 Mar;31(3):378–385. [PubMed]
  • Clements PJ, Opelz G, Terasaki PI, Mickey MR, Furst D. Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma). Tissue Antigens. 1978 Apr;11(4):357–361. [PubMed]
  • Hughes P, Gelsthorpe K, Doughty RW, Rowell NR, Rosenthal FD, Sneddon IB. The association of HLA-B8 with visceral disease in systemic sclerosis. Clin Exp Immunol. 1978 Mar;31(3):351–356. [PMC free article] [PubMed]
  • Ercilla MG, Arriaga F, Gratacós MR, Coll J, Lecha V, Vives J, Castillo R. HLA antigens and scleroderma. Arch Dermatol Res. 1981;271(4):381–385. [PubMed]
  • Kallenberg CG, Van der Voort-Beelen JM, D'Amaro J, The TH. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol. 1981 Mar;43(3):478–485. [PMC free article] [PubMed]
  • Lynch CJ, Singh G, Whiteside TL, Rodnan GP, Medsger TA, Jr, Rabin BS. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol. 1982 Oct;2(4):314–318. [PubMed]
  • Mollenhauer E, Schmidt R, Heinrichs M, Rittner C. Scleroderma: possible significance of silent alleles at the C4B locus. Arthritis Rheum. 1984 Jun;27(6):711–712. [PubMed]
  • DiBartolomeo AG, Rabin BS, Rodnan GP. HLA-D antigens in progressive systemic sclerosis (scleroderma). Immunol Commun. 1981;10(8):733–740. [PubMed]
  • Gladman DD, Keystone EC, Baron M, Lee P, Cane D, Mervert H. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum. 1981 Jun;24(6):854–856. [PubMed]
  • Germain BF, Espinoza LR, Bergen LL, Vagesh M, Vasey FB. Increased prevalence of DRw3 in the CREST syndrome. Arthritis Rheum. 1981 Jun;24(6):857–859. [PubMed]
  • Whiteside TL, Medsger TA, Jr, Rodnan GP. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1983 Feb;10(1):128–131. [PubMed]
  • Black CM, Welsh KI, Maddison PJ, Jayson MI, Bernstein RM. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol. 1984 Nov;23(4):267–271. [PubMed]
  • Alarcón GS, Phillips RM, Wasner CK, Acton RT, Barger BO. DR antigens in systemic sclerosis: lack of clinical correlations. Tissue Antigens. 1985 Aug;26(2):156–158. [PubMed]
  • Briggs DC, Welsh K, Pereira RS, Black CM. A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis. Arthritis Rheum. 1986 Oct;29(10):1274–1277. [PubMed]
  • Dunckley H, Jazwinska EC, Gatenby PA, Serjeantson SW. DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma. Tissue Antigens. 1989 Mar;33(3):418–420. [PubMed]
  • Birnbaum NS, Rodnan GP, Rabin BS, Bassion S. Histocompatibility antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1977 Winter;4(4):425–428. [PubMed]
  • Niks M, Rovenský J, Nyulassy S, Buc M, Stefanovic J, Zitnan D. Lack of association of HLA-DR antigens with progressive systemic sclerosis (scleroderma). Tissue Antigens. 1982 Mar;19(3):238–239. [PubMed]
  • Livingston JZ, Scott TE, Wigley FM, Anhalt GJ, Bias WB, McLean RH, Hochberg MC. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol. 1987 Jun;14(3):512–518. [PubMed]
  • Genth E, Mierau R, Genetzky P, von Mühlen CA, Kaufmann S, von Wilmowsky H, Meurer M, Krieg T, Pollmann HJ, Hartl PW. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990 May;33(5):657–665. [PubMed]
  • Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature. 317(6035):359–361. [PubMed]
  • Buus S, Colon S, Smith C, Freed JH, Miles C, Grey HM. Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3968–3971. [PMC free article] [PubMed]
  • Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. [PubMed]
  • Uryu N, Maeda M, Ota M, Tsuji K, Inoko H. A simple and rapid method for HLA-DRB and -DQB typing by digestion of PCR-amplified DNA with allele specific restriction endonucleases. Tissue Antigens. 1990 Jan;35(1):20–31. [PubMed]
  • Nomura N, Ota M, Tsuji K, Inoko H. HLA-DQB1 genotyping by a modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1991 Aug;38(2):53–59. [PubMed]
  • Ota M, Seki T, Nomura N, Sugimura K, Mizuki N, Fukushima H, Tsuji K, Inoko H. Modified PCR-RFLP method for HLA-DPB1 and -DQA1 genotyping. Tissue Antigens. 1991 Aug;38(2):60–71. [PubMed]
  • Ota M, Seki T, Fukushima H, Tsuji K, Inoko H. HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1992 Apr;39(4):187–202. [PubMed]
  • Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983 May;26(5):604–611. [PubMed]
  • Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978 Feb;69(2):103–120. [PubMed]
  • Inoko H, Ando A, Ito M, Tsuji K. Southern hybridization analysis of DNA polymorphism in the HLA-D region. Hum Immunol. 1986 Jul;16(3):304–313. [PubMed]
  • Naruse T, Nose Y, Tsuji K, Inoko H. Strong and unique associations of HLA-DPB1 alleles with other HLA antigens in a Japanese population. Tissue Antigens. 1992 May;39(5):276–279. [PubMed]
  • Reveille JD, Durban E, MacLeod-St Clair MJ, Goldstein R, Moreda R, Altman RD, Arnett FC. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest. 1992 Sep;90(3):973–980. [PMC free article] [PubMed]
  • Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8492–8496. [PMC free article] [PubMed]
  • D'Arpa P, White-Cooper H, Cleveland DW, Rothfield NF, Earnshaw WC. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum. 1990 Oct;33(10):1501–1511. [PubMed]
  • Verheijen R, Van den Hoogen F, Beijer R, Richter A, Penner E, Habets WJ, van Venrooij WJ. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol. 1990 Apr;80(1):38–43. [PMC free article] [PubMed]
  • Piccinini G, Cardellini E, Reimer G, Arnett FC, Durban E. An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients. Mol Immunol. 1991 Apr-May;28(4-5):333–339. [PubMed]
  • Sasazuki T, Kohno Y, Iwamoto I, Tanimura M, Naito S. Association between an HLA haplotype and low responsiveness to tetanus toxoid in man. Nature. 1978 Mar 23;272(5651):359–361. [PubMed]
  • Nishimura Y, Sasazuki T. Suppressor T cells control the HLA-linked low responsiveness to streptococcal antigen in man. Nature. 1983 Mar 3;302(5903):67–69. [PubMed]
  • Sasazuki T, Kaneoka H, Nishimura Y, Kaneoka R, Hayama M, Ohkuni H. An HLA-linked immune suppression gene in man. J Exp Med. 1980 Aug 1;152(2 Pt 2):297s–313s. [PubMed]
  • Hirayama K, Matsushita S, Kikuchi I, Iuchi M, Ohta N, Sasazuki T. HLA-DQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans. Nature. 1987 Jun 4;327(6121):426–430. [PubMed]
  • Kamikawaji N, Fujisawa K, Yoshizumi H, Fukunaga M, Yasunami M, Kimura A, Nishimura Y, Sasazuki T. HLA-DQ-restricted CD4+ T cells specific to streptococcal antigen present in low but not in high responders. J Immunol. 1991 Apr 15;146(8):2560–2567. [PubMed]
  • Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest. 1992 Apr;89(4):1208–1213. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...